Title 21, Food and DrugsRelease 119-110

§379j–62 Authority to Assess and Use Outsourcing Facility Fees

Title 21 › CHAPTER 9 — FEDERAL FOOD, DRUG, AND COSMETIC ACT › SUBCHAPTER VII — GENERAL AUTHORITY › Part C — Fees › subpart 9 — fees relating to outsourcing facilities › § 379j–62

Last updated Sep 22, 2026|Official source

Summary

Starting in fiscal year 2015, the Secretary must charge every outsourcing facility an annual establishment fee and must charge a reinspection fee each time the facility is reinspected. The Secretary sets the fees each year using the rules below and must publish the fee amounts in the Federal Register at least 60 days before the year starts. The basic fee numbers are $15,000 for the annual establishment fee and $15,000 for each reinspection, both adjusted each year for inflation. The inflation change is calculated from recent FDA pay changes and the Consumer Price Index, weighted between personnel and other costs, and compounded year to year. Small businesses with gross annual sales of $1,000,000 or less for the 12 months ending April 1 of the prior year pay one‑third of the base $15,000 amount if they apply in writing by April 30 of that prior year in the format the Secretary requires. The Secretary also sets a small business adjustment so total fees collected match what would have been collected if no one got the small business discount, and must credit any overestimate to the next year. An establishment fee is due when a facility submits its annual registration. Reinspection fees are collected after a reinspection in the manner and on the timeline the Secretary announces. If fees are not paid, a facility is not considered registered for that year, its drugs are treated as misbranded until fees are paid, and unpaid fees not paid within 30 calendar days become a government claim collectible under federal law. All fees collected must be used only to pay the costs of overseeing outsourcing facilities. Fee money must add to, not replace, other federal funding for these activities. Fees are collected and spent only as allowed by appropriations acts and may remain available until spent. The Secretary may transfer needed sums from FDA accounts to pay oversight costs. Within 120 calendar days after each fiscal year, the Secretary must report to Congress on fees collected, who paid them, hiring and staff placement, how fee funds were used for inspections, and the number of inspections and reinspections. For fiscal year 2014 and later years, Congress may appropriate an amount equal to the total fees assessed.

Full Legal Text

Title 21, §379j–62

Food and Drugs, Source: USLM XML via OLRC

(a)Establishment and reinspection fees
(1)In general
For fiscal year 2015 and each subsequent fiscal year, the Secretary shall, in accordance with this subsection, assess and collect—
(A)an annual establishment fee from each outsourcing facility; and
(B)a reinspection fee from each outsourcing facility subject to a reinspection in such fiscal year.
(2)Multiple reinspections
An outsourcing facility subject to multiple reinspections in a fiscal year shall be subject to a reinspection fee for each reinspection.
(b)Establishment and reinspection fee setting
The Secretary shall—
(1)establish the amount of the establishment fee and reinspection fee to be collected under this section for each fiscal year based on the methodology described in subsection (c); and
(2)publish such fee amounts in a Federal Register notice not later than 60 calendar days before the start of each such year.
(c)Amount of establishment fee and reinspection fee
(1)In general
For each outsourcing facility in a fiscal year—
(A)except as provided in paragraph (4), the amount of the annual establishment fee under subsection (b) shall be equal to the sum of—
(i)$15,000, multiplied by the inflation adjustment factor described in paragraph (2); plus
(ii)the small business adjustment factor described in paragraph (3); and
(B)the amount of any reinspection fee (if applicable) under subsection (b) shall be equal to $15,000, multiplied by the inflation adjustment factor described in paragraph (2).
(2)Inflation adjustment factor (3) Small business adjustment factor (4) Exception for small businesses
(A)In general
For fiscal year 2015 and subsequent fiscal years, the fee amounts established in paragraph (1) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year by the amount equal to the sum of— (i)
(ii)the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of an average full-time equivalent position of the Food and Drug Administration for the first 3 years of the preceding 4 fiscal years; plus
(iii)the average annual percent change that occurred in the Consumer Price Index for urban consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of an average full-time equivalent position of the Food and Drug Administration for the first 3 years of the preceding 4 fiscal years.
(B)Compounded basis
The adjustment made each fiscal year under subparagraph (A) shall be added on a compounded basis to the sum of all adjustments made each fiscal year after fiscal year 2014 under subparagraph (A).
(5)Crediting of fees
In establishing the small business adjustment factor under paragraph (3) for a fiscal year, the Secretary shall—
(A)provide for the crediting of fees from the previous year to the next year if the Secretary overestimated the amount of the small business adjustment factor for such previous fiscal year; and
(B)consider the need to account for any adjustment of fees and such other factors as the Secretary determines appropriate.
(d)Use of fees
The Secretary shall make all of the fees collected pursuant to subparagraphs (A) and (B) of subsection (a)(1) available solely to pay for the costs of oversight of outsourcing facilities.
(e)Supplement not supplant
Funds received by the Secretary pursuant to this section shall be used to supplement and not supplant any other Federal funds available to carry out the activities described in this section.
(f)Crediting and availability of fees
Fees authorized under this section shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation. The sums transferred shall be available solely for the purpose of paying the costs of oversight of outsourcing facilities.
(g)Collection of fees
(1)Establishment fee
An outsourcing facility shall remit the establishment fee due under this section in a fiscal year when submitting a registration pursuant to section 353b(b) of this title for such fiscal year.
(2)Reinspection fee
The Secretary shall specify in the Federal Register notice described in subsection (b)(2) the manner in which reinspection fees assessed under this section shall be collected and the timeline for payment of such fees. Such a fee shall be collected after the Secretary has conducted a reinspection of the outsourcing facility involved.
(3)Effect of failure to pay fees
(A)Registration
An outsourcing facility shall not be considered registered under section 353b(b) of this title in a fiscal year until the date that the outsourcing facility remits the establishment fee under this subsection for such fiscal year.
(B)Misbranding
All drugs manufactured, prepared, propagated, compounded, or processed by an outsourcing facility for which any establishment fee or reinspection fee has not been paid, as required by this section, shall be deemed misbranded under section 352 of this title until the fees owed for such outsourcing facility under this section have been paid.
(4)Collection of unpaid fees
In any case where the Secretary does not receive payment of a fee assessed under this section within 30 calendar days after it is due, such fee shall be treated as a claim of the United States Government subject to provisions of subchapter II of chapter 37 of title 31.
(h)Annual report to Congress
Not later than 120 calendar days after each fiscal year in which fees are assessed and collected under this section, the Secretary shall submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, to include a description of fees assessed and collected for such year, a summary description of entities paying the fees, a description of the hiring and placement of new staff, a description of the use of fee resources to support inspecting outsourcing facilities, and the number of inspections and reinspections of such facilities performed each year.
(i)Authorization of appropriations
For fiscal year 2014 and each subsequent fiscal year, there is authorized to be appropriated for fees under this section an amount equivalent to the total amount of fees assessed for such fiscal year under this section.

Reference

Citations & Metadata

Citation

21 U.S.C. § 379j–62

Title 21, Food and Drugs

Last Updated

Sep 22, 2026

Release point: 119-110